DERMALOG Identification Systems GmbH
Biometrics for Increased Driving Safety: Rheinmetall Dermalog SensorTec presents Innovative Technologies at InCabin 2024
mehr
Storys aus Hamburg, Germany
- Sprache:
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
Statista is transforming the data research experience with the introduction of Research AI
mehrAhrenkiel and Rohden join forces to form blue² ship management in Hamburg
Hamburg, Germany and Bern, Switzerland (ots) - Ahrenkiel, boasting a 125-year shipping history, and Rohden, representing five generations of ship management, have collaboratively founded blue² shipmanagement in Hamburg. blue², a sustainability-focused Swiss shipping firm, is keen to solidify its presence in Hamburg with Rohden's partnership. By merging the in-depth ...
mehr- 2
Telio Group Enters North American Market
mehr Dissolution of licence agreements in Germany: Avis-Budget loses station infrastructure in 7 of 16 German states
Hamburg, Germany (ots) - - Avis-Budget surprisingly terminates licensees - Station network in 7 of 16 German federal states becomes independent After 30 years of successful cooperation, Avis-Budget and the German licensee Wucherpfennig & Krohn will go their separate ways from 31. 12. 2023. The contract was ...
mehrdpa Deutsche Presse-Agentur GmbH
Fact-checkers in Germany and Austria launch alliance against disinformation
mehrSysmex Inostics and Oxford Gene Technology plasma and tissue sequencing show clearance of ctDNA correlates with pathologic complete response in breast cancer patients during neoadjuvant treatment
Hamburg, Germany and Baltimore, Maryland (ots) - Pathologist Dr. Vincente Peg of the Vall d´Hebron University Hospital (Barcelona Spain) and colleagues have presented a correlation between the clearance of circulating tumor DNA (ctDNA) in HER2-positive or triple-negative breast cancer patients undergoing ...
mehrSysmex Inostics announces first results of tissue-independent liquid biopsy for early stage breast cancer mutation characterization and monitoring using ultra-sensitive SafeSEQ technology
Hamburg, Germany and Baltimore, Maryland (ots) - New data presented by Dr. Ben Ho Park, Professor of Medicine and Director of Precision Oncology at Vanderbilt University and colleagues at the recent San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas demonstrated a potential utility for monitoring ...
mehrSysmex Inostics launches two NGS-based liquid biopsy panels for cancer therapy drug development
Hamburg, Germany and Baltimore, Maryland (ots) - Sysmex Inostics announces the availability of the SafeSEQ Breast Cancer and Head and Neck Cancer Panels along with the SafeSEQ Rapid Custom Development program for circulating tumor DNA (ctDNA) analysis. SafeSEQ is a next-generation sequencing (NGS)-based approach that delivers sensitivity comparable to the clinically ...
mehrLiquid Biopsy performance comparison of Sysmex Inostics OncoBEAM RAS CRC and BioCartis Idylla ctKRAS testing published in Scientific Reports (Nature Journal)
Hamburg, Germany (ots) - Sysmex Inostics, a global leader in blood based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology, today announces publication of a study comparing the performance of plasma RAS mutation detection by two commercial liquid biopsy testing platforms, the OncoBEAM(TM) ...
mehrSysmex Inostics' OncoBEAM(TM) demonstrates clinical validity and superior performance versus pan-cancer NGS for blood-based mutation detection for hepatocellular carcinoma
Hamburg, Germany (ots) - Data recently published in Clinical Cancer Research (http://ots.de/0ZGZkf) the advantages of using an ultra-high sensitivity test for detection of mutations which may predict therapeutic efficacy for hepatocellular carcinoma (HCC). Sysmex Inostics' OncoBEAM technology, a highly clinically ...
mehrSysmex Inostics OncoBEAM(TM) circulating tumor DNA technology demonstrates superior response prediction for advanced pancreatic cancer over standard-of-care protein biomarkers
Hamburg, Germany (ots) - Recent data published in Annals of Oncology (https://academic.oup.com/annonc/advance-article/doi/10.1093/annonc/mdy417/5139593) from a study conducted by Sysmex Inostics and University of Munich indicate that circulating tumor DNA (ctDNA) may offer clinicians higher-resolution information ...
mehrSysmex Inostics' OncoBEAM(TM) platform demonstrates superior detection of clinically-relevant mutations for therapy selection and molecular monitoring for lung and colon cancers
Hamburg, Germany (ots) - Data presented at the European Society of Medical Oncology (ESMO) 2018 meeting in Munich, Germany by three clinical oncology research groups demonstrate the importance of a highly sensitive test for detection of clinically-relevant mutations present in circulating tumor DNA (ctDNA) derived ...
mehrSysmex Inostics' OncoBEAM(TM) liquid biopsy technology demonstrates utility for clinical management of melanoma patients undergoing treatment with targeted therapy and immune checkpoint inhibitors
Hamburg, Germany (ots) - Sysmex Inostics, a pioneer in blood-based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology, is pleased to announce publication of a study in the Journal of Molecular Oncology highlighting the important clinical value of blood-based ctDNA mutation testing to ...
mehr
1